期刊
BRITISH JOURNAL OF CANCER
卷 117, 期 8, 页码 1089-1098出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2017.281
关键词
apoptosis; acute myeloid leukaemia; BCL2; MDM2; XIAP
类别
资金
- Amgen
- Astra-Zeneca
- Bayer
- Blueprint Medicines
- Bristol Myers Squib
- Celgene
- Lilly
- Merck Serono
- Merck Sharp Dohme
- Novartis
- Roche/Genentech
- Pfizer
Acute myeloid leukaemia (AML) is a molecularly and clinically heterogeneous disease, and its incidence is increasing as the populations in Western countries age. Despite major advances in understanding the genetic landscape of AML and its impact on the biology of the disease, standard therapy has not changed significantly in the last three decades. Allogeneic haematopoietic stem cell transplantation remains the best chance for cure, but can only be offered to a minority of younger fit patients. Molecularly targeted drugs aiming at restoring apoptosis in leukaemic cells have shown encouraging activity in early clinical trials and some of these drugs are currently being evaluated in randomised controlled trials. In this review, we discuss the current development of drugs designed to trigger cell death in AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据